NextCure NXTC
NASDAQ NXTC
$6.40 +0.17 (+2.73%)
At close: Nov 13, 2026 · 4:00 PM EST

NextCure (NXTC) Current Deferred Revenue (2018 - 2019)

Updated

NextCure's Current Deferred Revenue came in at $6.43 million for Q4 2019, up 28.8% from $4.99 million a year earlier and up 3.7% from the prior quarter.

Analysis

NextCure (NXTC) Current Deferred Revenue (2018 - 2019) Analysis & Trends

Going back to Q4 2018, NextCure's Current Deferred Revenue data covers 5 quarters.

  • Going back by year, Current Deferred Revenue was $4.99 million in FY2018.
  • The five-year range for quarterly Current Deferred Revenue is $4.99 million (Q4 2018) to $20.63 million (Q1 2019).
  • Business Quant data shows NXTC's Current Deferred Revenue at $6.2 million (Q3 2019), $6.52 million (Q2 2019) and $20.63 million (Q1 2019) in the three quarters before Q4 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn
10 NextCure 29.30 Mn -71.08 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 6.43 Mn
Sep 30, 2019 6.20 Mn
Jun 30, 2019 6.52 Mn
Mar 31, 2019 20.63 Mn
Dec 31, 2018 4.99 Mn
API Access

NextCure Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=NXTC&period=max&api_key=YOUR_API_KEY